Filter by Event: IDWeek 2022
Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals
Activity of SPR206 and Comparator Agents Against Pseudomonas aeruginosa and Acinetobacter baumannii Causing Infections in United States Hospitals. Lead Author: Rodrigo E. Mendes. Presented at IDWeek 2022, October 19-23, Washington DC.
Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel β-Lactam/β-Lactamase Inhibitor Combinations and Other β-Lactam Agents
Induction of Resistance Against Antipseudomonal Agents: Comparison of Novel β-Lactam/β-Lactamase Inhibitor Combinations and Other
β-Lactam Agents. Lead author: Mariana Castanheira. IDWeek 2022. October 19-21. Washington DC.
Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019–2021)
Antimicrobial Activity of Aztreonam-Avibactam Against Enterobacterales Causing Infection in United States Hospitals (2019–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.
In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Clinical Isolates of Enterobacterales Causing Infections in United States Hospitals (2020–2021)
In Vitro Activity of Cefiderocol and Comparator Agents Against Molecularly Characterized Clinical Isolates of Enterobacterales Causing Infections in United States Hospitals (2020–2021). Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.
In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals
In vitro Activity of SPR206 and Comparator Compounds against Enterobacterales Isolates Responsible for Infections in United States Hospitals. Lead author: Rodrigo Mendes. Presented at IDWeek 2022. October 19-21, 2022. Washington DC.
Oritavancin Activity Against Gram-Positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units in US Medical Centers (2010–2019)
Oritavancin Activity Against Gram-Positive Pathogens Causing Bloodstream Infections in Hematology/Oncology and Transplant Units
in US Medical Centers (2010–2019). Lead Author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.
Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021)
Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.
Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014–2021
Trends in the Susceptibility of US Acinetobacter baumannii-calcoaceticus Species Complex and Stenotrophomonas maltophilia Isolates to Minocycline, 2014–2021. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.
Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021
Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021. Lead author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.
Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021)
Aztreonam-Avibactam Activity against a Large Collection of Carbapenem-Resistant Enterobacterales (CRE) Collected in Hospitals from Europe, Asia, and Latin America (2019–2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.
Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019–2020)
Activity of Gepotidacin Tested Against Molecularly Characterized Escherichia coli Isolates Resistant to Commonly Used Oral Therapies for UTI in the US (2019–2020). Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.
Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex Clinical Isolates Causing Infection in United States Hospitals (2020–2021)
Cefiderocol In vitro Activity Against Molecularly Characterized Pseudomonas aeruginosa and Acinetobacter baumannii-calcoaceticus Complex Clinical Isolates Causing Infection in United States Hospitals (2020–2021). IDWeek 2022. October 19-21, 2022. Washington DC.
Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations Against AmpC-Producing Species Collected in United States Hospitals
Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations Against AmpC-Producing Species Collected in United States Hospitals. Lead Author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.
Dual VIM-Producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program
Dual VIM-Producing Proteus mirabilis, Including a Novel VIM-75, Among Elderly Patients in a Medical Center from Hungary: Report from the 2020 SENTRY Antimicrobial Surveillance Program. Lead Author: Gauri Deshpande; Presented by: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.
Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021)
Comparative Activity of Newer β-Lactam/β-Lactamase Inhibitor Combinations against Pseudomonas aeruginosa Isolates from United States Medical Centers (2020-2021). Lead Author: HS Sader at IDWeek 2022, October 19-23, Washington DC.
In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020–2021) Stratified by Infection Type
In Vitro Activity of Manogepix Against 2,810 Fungal Isolates from the SENTRY Surveillance Program (2020–2021) Stratified by Infection Type. Lead Author: Mike Huband, IDWeek 2022, October 19-21, Washington DC.
In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations
In Vitro Activity of Isavuconazole and Other Mould-Active Triazoles Against Aspergillus fumigatus With and Without cyp51 Alterations. Lead Author: Cecilia Carvalhaes, IDWeek 2022, October 19-21, Washington DC.
Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021)
Antimicrobial Activity of Ceftibuten-Avibactam against a Global Collection of Enterobacterales from Patients with Complicated Urinary Tract Infections (2021). Lead author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.
Increase in the Occurrence of Carbapenem-Resistant Enterobacterales in United States Hospitals from 2019 to 2021 and Activity of Novel β-Lactam/ β-Lactamase Inhibitor Combinations Against These Isolates
Increase in the Occurrence of Carbapenem-Resistant Enterobacterales in United States Hospitals from 2019 to 2021 and Activity of Novel β-Lactam/
β-Lactamase Inhibitor Combinations Against These Isolates. Lead author: Mariana Castanheira, IDWeek 2022, October 19-21, Washington DC.
Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the United States
Activity of Gepotidacin Against Escherichia coli Isolates from Community-acquired Urinary Tract Infections Collected Between 2019-2021 in the
United States. Lead Author: Rodrigo Mendes. IDWeek 2022. October 19-21, 2022. Washington DC.
Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016–2021)
Antimicrobial Activity of Aztreonam-Avibactam Against a Large Collection of Stenotrophomonas maltophilia and Burkholderia cepacia Species Complex Causing Infections in United States (US) Medical Centers (2016–2021). Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.
In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)
In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.
Activity of Oritavancin and Comparator Agents Against Coagulase-Negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019)
Activity of Oritavancin and Comparator Agents Against Coagulase-Negative Staphylococci Causing Bloodstream Infections in US Medical Centers (2017-2019). Lead author: Cecilia G Carvalhaes, IDWeek 2022, October 19-23, Washington DC.
Activity of Meropenem-Vaborbactam and Comparators Against Enterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States
Activity of Meropenem-Vaborbactam and Comparators AgainstEnterobacterales Isolates from Patients in Hematology/Oncology and Transplant Units in the United States. Lead author: Dee Shortridge, IDWeek 2022, October 19-23, Washington DC.
Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic Fibrosis Patients
Antimicrobial Activity of Aztreonam-Avibactam, Ceftazidime-Avibactam, and Comparator Agents against Pseudomonas aeruginosa from Cystic
Fibrosis Patients. Lead Author: Helio Sader, IDWeek 2022, October 19-21, Washington DC.
Prevalence, Phenotypic and Genotypic Characteristics, and Clinical Presentations of Staphylococcus argenteus Causing Bloodstream Infections in United States Hospitals
Prevalence, Phenotypic and Genotypic Characteristics, and Clinical Presentations of Staphylococcus argenteus Causing Bloodstream Infections in United States Hospitals. Lead author: Rodrigo Mendes, IDWeek 2022, October 19-21, Washington DC.
In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021)
In Vitro Evaluation of Delafloxacin Activity Against Contemporary US Isolates from Cystic Fibrosis Patients Hospitalized with Pneumonia: Results from the SENTRY Antimicrobial Surveillance Program (2019–2021). Lead author: Dee Shortridge, IDWeek 2022, October 19-21, Washington DC.
Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017–2021)
Azole Activity against Filamentous Fungi Causing Invasive Infections in Patients from ICU and Non-ICU Units (2017–2021). Lead author: Cecilia Carvalhaes, IDWeek 2022, October 18-21, Washington DC.
